<h4>Background</h4>Glucagon-like peptide 1 receptor agonists have been shown to reduce all-cause and cardiovascular mortality in patients with Type 2 diabetes mellitus (T2DM). Here, GLP1R is linked to type 2 diabetes mellitus.